Capricor Therapeutics (NASDAQ:CAPR) Rating Increased to Strong-Buy at LADENBURG THALM/SH SH

Capricor Therapeutics (NASDAQ:CAPR) was upgraded by stock analysts at LADENBURG THALM/SH SH to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

A number of other analysts have also recently weighed in on the stock. Piper Sandler reiterated an “overweight” rating and set a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. B. Riley Financial lifted their price objective on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. Finally, Cantor Fitzgerald set a $62.00 price target on Capricor Therapeutics and gave the stock an “overweight” rating in a report on Friday, March 13th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Capricor Therapeutics has an average rating of “Moderate Buy” and an average target price of $50.30.

Capricor Therapeutics Trading Down 13.0%

CAPR stock opened at $26.44 on Thursday. The company has a market capitalization of $1.53 billion, a P/E ratio of -11.40 and a beta of 0.39. Capricor Therapeutics has a twelve month low of $4.30 and a twelve month high of $40.37. The business has a 50 day simple moving average of $30.00 and a 200-day simple moving average of $28.41.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). Research analysts predict that Capricor Therapeutics will post -0.75 EPS for the current fiscal year.

Insider Buying and Selling at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $31.70, for a total value of $792,500.00. Following the transaction, the chief financial officer directly owned 8,223 shares of the company’s stock, valued at approximately $260,669.10. The trade was a 75.25% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Karimah Es Sabar sold 7,529 shares of the company’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total transaction of $240,928.00. Following the transaction, the director owned 7,529 shares of the company’s stock, valued at approximately $240,928. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 173,429 shares of company stock valued at $5,329,440. Corporate insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CAPR. Vanguard Group Inc. raised its holdings in Capricor Therapeutics by 16.1% during the fourth quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock worth $73,936,000 after purchasing an additional 355,161 shares in the last quarter. Suvretta Capital Management LLC purchased a new stake in Capricor Therapeutics in the 4th quarter valued at approximately $51,533,000. Tang Capital Management LLC purchased a new stake in Capricor Therapeutics in the 4th quarter valued at approximately $49,062,000. RA Capital Management L.P. acquired a new position in Capricor Therapeutics during the 4th quarter worth approximately $43,516,000. Finally, Geode Capital Management LLC increased its position in Capricor Therapeutics by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock worth $29,367,000 after purchasing an additional 55,766 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.